Bethlehem's Saladax Biomedical has hired two key executives as it prepares for the rollout of three products under its My Care portfolio of diagnostics.
Jonathan Mayo has been appointed vice president of sales for the U.S. market and Michael Duda has been named vice president of clinical laboratory operations.
Michael Parks, a spokesman for the company, said it will begin to market the products to physicians in the oncology field starting in June.
The My Care products are intended to help an oncologist dose patients within the best therapeutic range.
Currently, Parks said, oncologists base dosage on total body surface.
"It works well," Parks said. "But, the reality is every patient is different."
These products, he said, will improve the doctor's ability to make dosing decisions.
Mayo will help with the launch of the products in the U.S., and Mayo will be in charge of maintaining quality in the lab work – both areas that will need strong leadership moving into the next phase, said Parks.
Duda, recently a laboratory operations consultant to Saladax, has nearly 25 years of clinical laboratory experience supported by a strong background in analytical chemistry. Prior to his role as a consultant, Duda held several positions at LabCorp, serving most recently as vice president of LabCorp's clinical trials U.S. operations.
Mayo has more than 20 years in commercial oncology, pathology and molecular laboratory experience, as well as extensive clinical sales expertise.
Formed in 2004, Saladax works in many aspects of the pharmaceutical and biomedical industries.